Oryzon Genomics, S.A.

1:00 PM - 1:15 PM, Tuesday, June 4,2019 ・ Theater 2
Oryzon is a public clinical stage biopharmaceutical company listed on the Madrid stock exchange and a European leader in the development of epigenetics-based therapies. Oryzon has programs in clinical phase: CNS - Vafidemstat (ORY-2001), a dual LSD1-MAOB inhibitor, currently in three Phase IIA: • "ETHERAL": in mild to moderate AD • "REIMAGINE": aggression in adult population with Alzheimer’s Disease (AD), Lewy Body Dementia (LBD), Adult attention deficit hyperactivity disorder (ADHD), Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD) • "SATEEN": in relapse-remitting and secondary progressive forms of MS. Oncology – Iadademstat (ORY-1001), a selective LSD1 inhibitor, currently in two Phase IIA: • "ALICE": in AML • "CLEPSIDRA": in SCLC A third epigenetic compound (ORY-3001), also against LSD1, has completed the preclinical development, for a yet undisclosed non-oncological indication. -
Speaker
photo
CSO
Oryzon Genomics, S.A.